Neuroendocrine Cancer

Neuroendocrine tumors (NETs), also called neuroendocrine cancer, are rare tumors that develop from specialized cells called neuroendocrine cells, which are found throughout the body and have traits of both nerve cells and hormone-producing cells. Approximately 12,000-15,000 new cases are diagnosed worldwide each year, though the actual number may be higher since these tumors are often difficult to diagnose. NETs can arise almost anywhere but most commonly develop in the digestive system (stomach, intestines, appendix, rectum), pancreas, or lungs. These tumors vary dramatically in behavior—some grow very slowly over years while others are more aggressive. Many NETs produce hormones that cause distinctive symptoms: excessive serotonin can cause carcinoid syndrome with flushing, diarrhea, and heart valve problems, while pancreatic NETs can produce insulin (causing low blood sugar), gastrin (causing ulcers), or other hormones. Tumors are classified by grade (G1, G2, G3) based on how rapidly cells are dividing under the microscope, with well-differentiated tumors generally growing slowly and poorly differentiated neuroendocrine carcinomas behaving more aggressively. The exact causes aren't well understood, though some people inherit genetic syndromes (like Multiple Endocrine Neoplasia or Von Hippel-Lindau) that increase risk. Many NETs are discovered incidentally during imaging or procedures for other reasons, since symptoms can be vague or absent in early stages.

Surgery remains the primary treatment for localized NETs and can be curative when tumors are completely removable. For tumors that can't be surgically removed or have spread, somatostatin analogues—drugs including octreotide and lanreotide given by injection—are standard therapy. These medications control hormone-related symptoms and also slow tumor growth in many patients. A major advance was approval of peptide receptor radionuclide therapy (PRRT), particularly lutetium-177 DOTATATE (Lutathera), which delivers targeted radiation directly to tumor cells by attaching radioactive particles to molecules that bind to receptors abundant on NET cells. PRRT has significantly extended survival for many patients with progressive disease. Targeted therapies including everolimus (which blocks mTOR, a protein involved in cell growth) and sunitinib (which inhibits blood vessel formation) are approved for pancreatic NETs and provide additional treatment options. For higher-grade neuroendocrine carcinomas that behave more like typical cancers, platinum-based chemotherapy is standard. Liver-directed therapies including embolization, ablation, and selective internal radiation therapy treat liver metastases, which are common in NETs. Symptom management is important—medications control diarrhea and flushing, and nutritional support addresses digestive issues. Many people with well-differentiated, slow-growing NETs live for years or even decades with disease, managing it as a chronic condition rather than facing immediate life-threatening progression.

Treatment options become limited after disease progresses through available therapies, particularly after PRRT—identifying what to use next remains challenging. High-grade neuroendocrine carcinomas (grade 3, poorly differentiated) respond less well to treatments that work for well-differentiated NETs, and these aggressive tumors need better therapeutic options beyond chemotherapy. The rarity and diversity of NETs makes conducting large clinical trials difficult, slowing drug development compared to more common cancers. Not all NETs express high levels of somatostatin receptors, making them ineligible for PRRT and limiting treatment options for this subset. Better biomarkers to predict which patients will respond to specific treatments would enable more personalized therapy selection and help avoid ineffective treatments. Functional symptoms from hormone production can be extremely difficult to manage when somatostatin analogues become less effective over time. NETs can be heterogeneous, meaning different tumor deposits in the same patient may have different characteristics and treatment sensitivities, complicating treatment approaches. Some people experience long-term effects from PRRT including kidney damage and bone marrow suppression that can limit further treatment options. Early diagnosis remains challenging since symptoms are often vague and easily attributed to other common conditions, with many patients experiencing symptoms for years before receiving the correct diagnosis.

Next-generation peptide receptor radionuclide therapies using different isotopes are in Phase 2 and Phase 3 trials, including actinium-225 (an alpha-emitter delivering more powerful radiation over shorter distances) and yttrium-90 labeled compounds. These aim to treat tumors resistant to lutetium-177 or provide more potent alternatives. Combination PRRT approaches pairing radionuclide therapy with chemotherapy or targeted drugs are being evaluated to enhance effectiveness. Novel somatostatin analogues with improved binding characteristics and longer action are in development. Immunotherapy trials are testing checkpoint inhibitors, though early results suggest NETs generally respond less well than other cancers to standard immunotherapy—researchers are exploring why and testing combination approaches to overcome resistance. Cabozantinib, a multi-targeted kinase inhibitor, showed promising activity in Phase 2 trials for pancreatic NETs and is being studied further. For higher-grade neuroendocrine carcinomas, trials are testing whether adding immunotherapy to chemotherapy improves outcomes. PARP inhibitors, which block DNA repair mechanisms, are being evaluated for NETs with specific genetic features. Somatostatin receptor antagonists (rather than the current analogues which are agonists) are being tested based on evidence they might have stronger anti-tumor effects. Researchers are exploring whether combining PRRT with drugs that increase somatostatin receptor expression on tumors could enhance treatment effectiveness.

Theranostic approaches pairing diagnostic imaging with matched therapies are being refined, using the same targeting molecule for both detecting tumors (attached to imaging tracers) and treating them (attached to therapeutic radiation). Scientists are developing CAR-T cell therapies engineered to recognize somatostatin receptors or other markers on NET cells, though penetrating solid tumors and surviving in the tumor environment remain challenges being addressed. Researchers are investigating the tumor microenvironment—the blood vessels, immune cells, and supportive tissue surrounding NETs—to identify new drug targets and understand why these tumors often resist immunotherapy. Liquid biopsies detecting tumor DNA and circulating tumor cells in blood are being refined for earlier detection of progression, treatment monitoring, and possibly screening people with genetic syndromes predisposing to NETs. Artificial intelligence is being applied to predict treatment responses based on imaging patterns, genetic profiles, and clinical characteristics. Novel radioisotopes and chelating molecules are being developed to improve PRRT delivery and effectiveness. Scientists are exploring drugs that target specific metabolic pathways NETs rely on for growth and survival. Researchers are investigating whether gut bacteria influence NET behavior and treatment response. Gene therapy approaches to restore normal cell function or enhance radiosensitivity are in early research. Scientists are working to understand NET tumor heterogeneity—why different areas of tumors behave differently—to develop treatments that address all tumor cell populations. Biomarker research aims to identify blood or imaging markers that predict who will benefit from specific treatments before starting therapy. Researchers are developing organoid models—miniature tumors grown from patient samples in the laboratory—to test multiple treatments and identify the most effective option for individual patients.